There is a great need for a robust small-animal model to optimize the development of FLT3 inhibitors. A recently generated FLT3-ITD knock-in mouse model showed that the mice developed a ...

Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...

FLT3 mutation is a highly relevant target given its specificity and role in the biology of AML. There are a number of small-molecule receptor tyrosine kinase inhibitors that target FLT3 ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

This type of AML can be treated with established drugs called FLT3 inhibitors, but the cancer often develops resistance to this treatment over time. Because the RSK1 inhibitor blocks a different ...

This is an electron microscopy visualization of AML cells treated with Flt3 inhibitor showing mitophagy. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases ...

Xospata, a FLT3 inhibitor, received an accelerated review, and the approval follows a positive CHMP recommendation in September. The FLT3 mutation is expressed in about 30% of AML patients and is ...